{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T23:12:08Z","timestamp":1788649928551,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s10147-025-02945-5","type":"journal-article","created":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T14:36:27Z","timestamp":1766241387000},"page":"336-346","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of baseline regular magnesium oxide administration on chemotherapy-induced constipation during cisplatin-containing treatment"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-9821-7917","authenticated-orcid":false,"given":"Yoshitaka","family":"Saito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoh","family":"Takekuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Sakakibara-Konishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,20]]},"reference":[{"key":"2945_CR1","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1200\/JCO.19.03136","volume":"38","author":"S Gadgeel","year":"2020","unstructured":"Gadgeel S, Rodr\u00edguez-Abreu D, Speranza G et al (2020) Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol 38:1505\u20131517. https:\/\/doi.org\/10.1200\/JCO.19.03136","journal-title":"J Clin Oncol"},{"key":"2945_CR2","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","volume":"378","author":"MA Socinski","year":"2018","unstructured":"Socinski MA, Jotte RM, Cappuzzo F et al (2018) Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 378:2288\u20132301. https:\/\/doi.org\/10.1056\/NEJMoa1716948","journal-title":"N Engl J Med"},{"key":"2945_CR3","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","volume":"22","author":"L Paz-Ares","year":"2021","unstructured":"Paz-Ares L, Ciuleanu TE, Cobo M et al (2021) First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol 22:198\u2013211. https:\/\/doi.org\/10.1016\/S1470-2045(20)30641-0","journal-title":"Lancet Oncol"},{"key":"2945_CR4","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1200\/JCO.22.00975","volume":"41","author":"ML Johnson","year":"2023","unstructured":"Johnson ML, Cho BC, Luft A et al (2023) Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: the phase III POSEIDON study. J Clin Oncol 41:1213\u20131227. https:\/\/doi.org\/10.1200\/JCO.22.00975","journal-title":"J Clin Oncol"},{"key":"2945_CR5","doi-asserted-by":"publisher","first-page":"3004","DOI":"10.1200\/JCO.2012.42.3749","volume":"31","author":"F Barlesi","year":"2013","unstructured":"Barlesi F, Scherpereel A, Rittmeyer A et al (2013) Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J Clin Oncol 31:3004\u20133011. https:\/\/doi.org\/10.1200\/JCO.2012.42.3749","journal-title":"J Clin Oncol"},{"key":"2945_CR6","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J et al (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636\u20132644. https:\/\/doi.org\/10.1200\/JCO.2003.11.136","journal-title":"J Clin Oncol"},{"key":"2945_CR7","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00520-016-3426-5","volume":"25","author":"Y Saito","year":"2017","unstructured":"Saito Y, Kobayashi M, Yamada T et al (2017) Premedication with intravenous magnesium has a protective effect against cisplatin-induced nephrotoxicity. Support Care Cancer 25:481\u2013487. https:\/\/doi.org\/10.1007\/s00520-016-3426-5","journal-title":"Support Care Cancer"},{"key":"2945_CR8","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s10147-024-02535-x","volume":"29","author":"H Iihara","year":"2024","unstructured":"Iihara H, Abe M, Wada M et al (2024) 2023 Japan Society of clinical oncology clinical practice guidelines update for antiemesis. Int J Clin Oncol 29:873\u2013888. https:\/\/doi.org\/10.1007\/s10147-024-02535-x","journal-title":"Int J Clin Oncol"},{"key":"2945_CR9","unstructured":"NCCN Clinical Practice Guidelines in Oncology, Antiemesis, version 2, 2025, Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf, Accessed June 22, 2025"},{"key":"2945_CR10","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1007\/s00520-006-0040-y","volume":"14","author":"RJ Gibson","year":"2006","unstructured":"Gibson RJ, Keefe DMK (2006) Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies. Support Care Cancer 14:890\u2013900. https:\/\/doi.org\/10.1007\/s00520-006-0040-y","journal-title":"Support Care Cancer"},{"key":"2945_CR11","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy148","author":"PJ Larkin","year":"2018","unstructured":"Larkin PJ, Cherny NI, La Carpia D et al (2018) Diagnosis, assessment and management of constipation in advanced cancer: ESMO clinical practice guidelines. Ann Oncol. https:\/\/doi.org\/10.1093\/annonc\/mdy148","journal-title":"Ann Oncol"},{"key":"2945_CR12","doi-asserted-by":"publisher","first-page":"4723","DOI":"10.1007\/s00520-021-06023-0","volume":"29","author":"S Kimura","year":"2021","unstructured":"Kimura S, Hosoya K, Ogata K et al (2021) Severity of constipation related to palonosetron during first-line chemotherapy: a retrospective observational study. Support Care Cancer 29:4723\u20134732. https:\/\/doi.org\/10.1007\/s00520-021-06023-0","journal-title":"Support Care Cancer"},{"key":"2945_CR13","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.31557\/APJCP.2021.22.9.3017","volume":"22","author":"I Neves Duarte Lisboa","year":"2021","unstructured":"Neves Duarte Lisboa I, Dantas De S\u00e1 Tin\u00f4co J, Dias Fernandes MIDC et al (2021) Constipation in chemotherapy patients: a diagnostic accuracy study. Asian Pac J Cancer Prev 22:3017\u20133021. https:\/\/doi.org\/10.31557\/APJCP.2021.22.9.3017","journal-title":"Asian Pac J Cancer Prev"},{"key":"2945_CR14","doi-asserted-by":"publisher","first-page":"8019","DOI":"10.1007\/s00520-022-07244-7","volume":"30","author":"Z Pehlivan","year":"2022","unstructured":"Pehlivan Z, Nural N (2022) Prevalence of constipation in patients undergoing chemotherapy and the effect of constipation on quality of life. Support Care Cancer 30:8019\u20138028. https:\/\/doi.org\/10.1007\/s00520-022-07244-7","journal-title":"Support Care Cancer"},{"key":"2945_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10147-020-01818-3","volume":"26","author":"K Aogi","year":"2021","unstructured":"Aogi K, Takeuchi H, Saeki T et al (2021) Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis. Int J Clin Oncol 26:1\u201317. https:\/\/doi.org\/10.1007\/s10147-020-01818-3","journal-title":"Int J Clin Oncol"},{"key":"2945_CR16","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1093\/annonc\/mdw220","volume":"27","author":"K Suzuki","year":"2016","unstructured":"Suzuki K, Yamanaka T, Hashimoto H et al (2016) Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study. Ann Oncol 27:1601\u20131606. https:\/\/doi.org\/10.1093\/annonc\/mdw220","journal-title":"Ann Oncol"},{"key":"2945_CR17","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1007\/s00520-013-1835-2","volume":"21","author":"S Miura","year":"2013","unstructured":"Miura S, Watanabe S, Sato K et al (2013) The efficacy of triplet antiemetic therapy with 0.75 mg of palonosetron for chemotherapy-induced nausea and vomiting in lung cancer patients receiving highly emetogenic chemotherapy. Support Care Cancer 21:2575\u20132581. https:\/\/doi.org\/10.1007\/s00520-013-1835-2","journal-title":"Support Care Cancer"},{"key":"2945_CR18","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s10637-023-01414-y","volume":"42","author":"D Tsuji","year":"2024","unstructured":"Tsuji D, Nakagaki S, Yonezawa I et al (2024) A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for a cisplatin-containing regimen.\u2014PATROL-I. Invest New Drugs 42:44\u201352. https:\/\/doi.org\/10.1007\/s10637-023-01414-y","journal-title":"Invest New Drugs"},{"key":"2945_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.crphar.2022.100152","volume":"4","author":"HT Rakshith","year":"2023","unstructured":"Rakshith HT, Lohita S, Rebello AP et al (2023) Sex differences in drug effects and\/or toxicity in oncology. Curr Res Pharmacol Drug Discov 4:100152. https:\/\/doi.org\/10.1016\/j.crphar.2022.100152","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"2945_CR20","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00520-019-05016-4","volume":"28","author":"A Davies","year":"2020","unstructured":"Davies A, Leach C, Caponero R et al (2020) MASCC recommendations on the management of constipation in patients with advanced cancer. Support Care Cancer 28:23\u201333. https:\/\/doi.org\/10.1007\/s00520-019-05016-4","journal-title":"Support Care Cancer"},{"key":"2945_CR21","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1007\/s11864-022-00976-y","volume":"23","author":"T Dzier\u017canowski","year":"2022","unstructured":"Dzier\u017canowski T, Mercadante S (2022) Constipation in cancer patients - an update of clinical evidence. Curr Treat Options Oncol 23:936\u2013950. https:\/\/doi.org\/10.1007\/s11864-022-00976-y","journal-title":"Curr Treat Options Oncol"},{"key":"2945_CR22","doi-asserted-by":"publisher","first-page":"421","DOI":"10.3390\/nu13020421","volume":"13","author":"H Mori","year":"2021","unstructured":"Mori H, Tack J, Suzuki H (2021) Magnesium oxide in constipation. Nutrients 13:421. https:\/\/doi.org\/10.3390\/nu13020421","journal-title":"Nutrients"},{"key":"2945_CR23","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1080\/17474124.2020.1708718","volume":"14","author":"I Aziz","year":"2020","unstructured":"Aziz I, Whitehead WE, Palsson OS et al (2020) An approach to the diagnosis and management of Rome IV functional disorders of chronic constipation. Expert Rev Gastroenterol Hepatol 14:39\u201346. https:\/\/doi.org\/10.1080\/17474124.2020.1708718","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2945_CR24","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ejphar.2013.08.049","volume":"722","author":"C Rojas","year":"2014","unstructured":"Rojas C, Raje M, Tsukamoto T et al (2014) Molecular mechanisms of 5-HT(3) and NK(1) receptor antagonists in prevention of emesis. Eur J Pharmacol 722:26\u201337. https:\/\/doi.org\/10.1016\/j.ejphar.2013.08.049","journal-title":"Eur J Pharmacol"},{"key":"2945_CR25","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1007\/s00228-021-03157-2","volume":"77","author":"YC Hsu","year":"2021","unstructured":"Hsu YC, Chen CY, Tam KW et al (2021) Effectiveness of palonosetron versus granisetron in preventing chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis. Eur J Clin Pharmacol 77:1597\u20131609. https:\/\/doi.org\/10.1007\/s00228-021-03157-2","journal-title":"Eur J Clin Pharmacol"},{"key":"2945_CR26","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1634\/theoncologist.2010-0198","volume":"16","author":"Z Likun","year":"2011","unstructured":"Likun Z, Xiang J, Yi B et al (2011) A systematic review and meta-analysis of intravenous palonosetron in the prevention of chemotherapy-induced nausea and vomiting in adults. Oncologist 16:207\u2013216. https:\/\/doi.org\/10.1634\/theoncologist.2010-0198","journal-title":"Oncologist"},{"key":"2945_CR27","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s13318-014-0175-z","volume":"40","author":"H Nakamura","year":"2015","unstructured":"Nakamura H, Yokoyama H, Takayanagi R et al (2015) Theoretical evaluation of antiemetic effects of 5-HT3 receptor antagonists for prevention of vomiting induced by cisplatin. Eur J Drug Metab Pharmacokinet 40:39\u201344. https:\/\/doi.org\/10.1007\/s13318-014-0175-z","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"2945_CR28","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1248\/bpb.b16-01001","volume":"40","author":"H Hayashi","year":"2017","unstructured":"Hayashi H, Suzuki A, Ohata K et al (2017) Control of constipation in patients receiving CHOP or CHOP-like chemotherapy regimens for non-Hodgkin\u2019s lymphoma. Biol Pharm Bull 40:698\u2013702. https:\/\/doi.org\/10.1248\/bpb.b16-01001","journal-title":"Biol Pharm Bull"},{"key":"2945_CR29","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1136\/gut.2010.227132","volume":"60","author":"AC Ford","year":"2011","unstructured":"Ford AC, Suares NC (2011) Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis. Gut 60:209\u2013218. https:\/\/doi.org\/10.1136\/gut.2010.227132","journal-title":"Gut"},{"key":"2945_CR30","doi-asserted-by":"publisher","first-page":"436","DOI":"10.3122\/jabfm.2011.04.100272","volume":"24","author":"L Leung","year":"2011","unstructured":"Leung L, Riutta T, Kotecha J et al (2011) Chronic constipation: an evidence-based review. J Am Board Fam Med 24:436\u2013451. https:\/\/doi.org\/10.3122\/jabfm.2011.04.100272","journal-title":"J Am Board Fam Med"},{"key":"2945_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12196148","volume":"12","author":"GS Sayuk","year":"2023","unstructured":"Sayuk GS, Yu QT, Shy C (2023) Management of constipation in hospitalized patients. J Clin Med 12:6148. https:\/\/doi.org\/10.3390\/jcm12196148","journal-title":"J Clin Med"},{"key":"2945_CR32","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1111\/jocn.12511","volume":"23","author":"E Noiesen","year":"2014","unstructured":"Noiesen E, Trosborg I, Bager L et al (2014) Constipation\u2014prevalence and incidence among medical patients acutely admitted to hospital with a medical condition. J Clin Nurs 23:2295\u20132302. https:\/\/doi.org\/10.1111\/jocn.12511","journal-title":"J Clin Nurs"},{"key":"2945_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/bmjquality.u212167.w3007","author":"R Jackson","year":"2016","unstructured":"Jackson R, Cheng P, Moreman S et al (2016) The constipation conundrum: improving recognition of constipation on a gastroenterology ward. BMJ Qual Improv Rep. https:\/\/doi.org\/10.1136\/bmjquality.u212167.w3007","journal-title":"BMJ Qual Improv Rep"},{"key":"2945_CR34","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.21873\/anticanres.15808","volume":"42","author":"Y Saito","year":"2022","unstructured":"Saito Y, Takekuma Y, Kobayashi M et al (2022) Suitability of oral rehydration solution (ORS) for use in the cisplatin short hydration method. Anticancer Res 42:3185\u20133193. https:\/\/doi.org\/10.21873\/anticanres.15808","journal-title":"Anticancer Res"},{"key":"2945_CR35","doi-asserted-by":"publisher","first-page":"21819","DOI":"10.1038\/s41598-022-26454-x","volume":"12","author":"Y Saito","year":"2022","unstructured":"Saito Y, Sakamoto T, Takekuma Y et al (2022) Diabetes mellitus degenerates cisplatin-induced nephrotoxicity in short hydration method: a propensity score-matching analysis. Sci Rep 12:21819. https:\/\/doi.org\/10.1038\/s41598-022-26454-x","journal-title":"Sci Rep"},{"key":"2945_CR36","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1080\/07315724.2020.1727380","volume":"39","author":"G Yurtda\u015f","year":"2020","unstructured":"Yurtda\u015f G, Acar-Tek N, Akbulut G et al (2020) Risk factors for constipation in adults: a cross-sectional study. J Am Coll Nutr 39:713\u2013719. https:\/\/doi.org\/10.1080\/07315724.2020.1727380","journal-title":"J Am Coll Nutr"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02945-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02945-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02945-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T04:08:04Z","timestamp":1769486884000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02945-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,20]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2945"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02945-5","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,20]]},"assertion":[{"value":"13 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethical Review Board for Life Science and Medical Research of Hokkaido University Hospital (approval number: 024\u20130432) and was performed in accordance with the ethical standards of the institutional and\/or national research committee and the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The requirement for informed consent from the participants was waived by the Ethical Review Board for Life Science and Medical Research of Hokkaido University Hospital, considering the retrospective nature of the present study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Formal consent was not required for this type of study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}